TheraRadar
Clinical-Stage Companies / Laboratorios Sophia S.A de C.V.

Laboratorios Sophia S.A de C.V.

Pre-Approval PRO BETA
43
Total Trials
10
Phase 3
6
Phase 2
2
Recruiting
286
Score

Pipeline by Phase

Phase 3
10
Phase 2
6
Phase 1
21

Therapeutic Focus

Dry Eye Myopia Dry Eye Syndromes Ocular Hypertension Conjunctivitis, Bacterial

Clinical Trials (43)

NCT07305987 Phase 3 RECRUITING

PRO-232 in Patients Subjected to Cataract Surgery

Started: 10/27/2025

NCT06389110 Phase 3 RECRUITING

Study to Evaluate the Efficacy of Alleance® (Atropine Sulfate 0.01%) as a Treatment to Delay Myopia and Axial Ocular Elongation in Children.

Started: 3/15/2025

NCT05217680 Phase 3 COMPLETED

Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema

Started: 5/24/2021

NCT03193333 Phase 3 TERMINATED

PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM)

Started: 11/6/2017

NCT02801617 Phase 3 TERMINATED

Non-inferiority of PRO-067 Ophthalmic Solution vs GAAP Ofteno® in Glaucoma or Ocular Hypertension

Started: 9/1/2015

NCT03696342 Phase 3 TERMINATED

Efficacy of the Ophthalmic Pazufloxacin 0.6% for Bacterial Conjunctivitis, Compared to Gatifloxacin 0.3%.

Started: 10/1/2018

NCT03257813 Phase 3 COMPLETED

Non-inferiority of PRO-122 Ophthalmic Solution vs KRYTANTEK Ofteno® in Glaucoma or Ocular Hypertension (CONFORTK)

Started: 4/1/2016

NCT03693989 Phase 3 COMPLETED

Clinical Study of the Efficacy of the Ophthalmic Emulsion PRO-145 for Inflammation and Pain After Phacoemulsification

Started: 10/4/2018

NCT01657240 Phase 3 WITHDRAWN

Clinical Efficacy of PRO-118 Compared With Olopatadine Hydrochloride Ophthalmic Solution in Allergic Conjunctivitis

Started: 11/1/2014

NCT01657253 Phase 3 COMPLETED

Efficacy and Safety of PRO-148 Versus Systane®, in Patients With Mild to Moderate Dry Eye

Started: 11/1/2013

NCT04704531 Phase 2 COMPLETED

Phase II Clinical Study to Evaluate the Efficacy of Multidose Lagricel® Ofteno Ophthalmic Solution as Treatment for Dry Eye Disease.

Started: 1/3/2022

NCT02980523 Phase 2 COMPLETED

Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin)

Started: 3/1/2015

NCT01541891 Phase 2 COMPLETED

Efficacy and Safety of PRO-148 Ophthalmic Solution Versus SYSTANE® in the Treatment of Patients With Dry Eye Syndrome

Started: 10/1/2011

NCT01657266 Phase 2 COMPLETED

Efficacy and Safety of PRO-155 Versus Nevanac in Post Phacoemulsification

Started: 12/1/2013

NCT01541904 Phase 2 WITHDRAWN

Efficacy and Safety of PRO-118 Ophthalmic Solution in Allergic Conjunctivitis

Started: 3/1/2011

NCT06352541 Phase 1 COMPLETED

Study Evaluating PRO-232 an Ophthalmic Solution Compared to Placebo.

Started: 2/8/2024

NCT07429474 Phase 1 NOT YET RECRUITING

Safety and Immunogenicity of PRO-169 in Patients With Diabetic Macular Edema

Started: 3/1/2026

NCT05470881 Phase 1 COMPLETED

Phase I Clinical Trial to Evaluate the Safety and Tolerability of Ophtalmic Solution PRO-201

Started: 8/20/2022

NCT03697876 Phase 1 COMPLETED

Safety and Tolerability of the Ophthalmic Gel PRO-165 Versus Artelac® Nightime Gel

Started: 8/20/2018

NCT05470868 Phase 1 COMPLETED

Safety and Tolerability of PRO-185

Started: 2/4/2023

NCT04693429 Phase 1 COMPLETED

Clinical Study for the Evaluation of Safety and Tolerability of PRO-172 Ophthalmic Solution+

Started: 9/24/2020

NCT04111965 Phase 1 COMPLETED

Clinical Trial to Compare the Safety and Efficacy of Nanodrop®

Started: 12/1/2020

NCT06363292 Phase 1 COMPLETED

Study to Evaluate the Safety and Tolerability of PRO-231 Versus VIGAMOXI® on the Ocular Surface of Healthy Subjects

Started: 1/30/2024

NCT06375343 Phase 1 NOT YET RECRUITING

Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive®

Started: 1/30/2026

NCT06379685 Phase 1 NOT YET RECRUITING

Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface.

Started: 12/30/2025

NCT06370585 Phase 1 COMPLETED

Clinical Study to Evaluate the Safety and Tolerability of PRO-229 Ophthalmic Solution Compared to Lagricel® Ofteno PF

Started: 5/16/2024

NCT05481489 Phase 1 WITHDRAWN

Safety and Tolerability Evaluation of PRO-230 Ophthalmic Solution

Started: 2/1/2023

NCT04081610 Phase 1 COMPLETED

Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution

Started: 9/9/2019

NCT03966365 Phase 1 COMPLETED

Safety and Tolerability of the Preservative-free Ophthalmic Solution PRO-122 Compared With Krytantek Ofteno®

Started: 5/2/2019

NCT03965052 Phase 1 COMPLETED

Safety and Tolerability of the Ophthalmic Solution PRO-179 Compared With Travatan®

Started: 4/24/2019

NCT01871077 Phase 1 COMPLETED

Safety and Tolerability of the Ophthalmic Solution PRO-156 in Ophthalmologically Healthy Volunteers.

Started: 9/1/2013

NCT03519516 Phase 1 COMPLETED

Safety and Tolerability of the PRO-174 Versus Sophixín Ofteno®, on the Ocular Surface of Healthy Subjects

Started: 1/25/2018

NCT01535443 Phase 1 COMPLETED

Safety and Tolerability of PRO-155 Ophthalmic Solution 0.09% in Healthy Volunteers.

Started: 9/1/2011

NCT03520348 Phase 1 COMPLETED

Safety and Tolerability of the Ophthalmic Gel PRO-167 Versus Corneregel® on Healthy Subjects.

Started: 10/4/2017

NCT03524157 Phase 1 COMPLETED

Safety and Tolerability of PRO-087 Versus Xyel Ofteno® and Systane Ultra®, on the Ocular Surface of Healthy Subjects

Started: 7/17/2017

NCT03698045 Phase 1 WITHDRAWN

Safety and Tolerability of PRO-143 Ophthalmic Solution in Healthy Volunteers.

Started: 11/1/2013

NCT06859476 Phase 4 COMPLETED

Evaluation of Manzanilla® and Meticel Ofteno® 0.5% for Providing a Relief Sensation to the Eyes

Started: 5/23/2025

NCT04704518 Phase 4 COMPLETED

Study to Evaluate the Efficacy of Lagricel® Ofteno PF Compared to Thealoz® Duo After Photorefractive Keratectomy

Started: 9/3/2022

NCT04702776 Phase 4 COMPLETED

Study to Compare the Efficacy of the Ophthalmic Solution Humylub Ofteno® PF With Hyabak® and Lagricel Ofteno® PF as Treatment for Dry Eye.

Started: 12/9/2021

NCT06373653 Phase 4 WITHDRAWN

Study of Non-inferiority Between Manzanilla Sophia® and Meticel Ofteno® 0.5% for Providing a Soothing Sensation to the Eyes.

Started: 2/11/2025

NCT04702789 Phase 4 TERMINATED

Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension.

Started: 10/19/2021

NCT03521791 Phase 4 COMPLETED

Efficacy and Safety of PRO-155 on Inflammation of the Conjunctival Surface in Subjects With Grade I-III Pterygium vs Placebo.

Started: 12/13/2017

NCT03223909 Phase 4 COMPLETED

Efficacy and Safety of the Ophthalmic Solution PRO-087 Versus Systane ® Ultra and Ultra Preservative Free (087LATAMFIV)

Started: 10/13/2016

Drug Candidates

PRO-232 Manzanilla Sophia® Meticel Ofteno® 0.5% Sodium Hyaluronate Ophthalmic 0.4% Trehalose 3% / Sodium Hyaluronate Ophthalmic 0.15% Bevacizumab Lucentis® PRO-169 Sodium Hyaluronate Ophthalmic 0.4% one drop twice a day (BID) Sodium Hyaluronate Ophthalmic 0.4% one drop four times a day (QID)
Activity Status: Active
Last Trial Started: 3/1/2026
Last Trial Ended: 11/25/2025
Trials (12 months): 5
Completed Trials: 29
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.